Plymouth, Minnesota firm ev3 has received US FDA 510(k) clearance to market its EverCross 0.035" and NanoCross 0.014" peripheral angioplasty balloon catheters. ev3 expects to begin full commercialisation of the balloons in January 2009. The devices are designed with innovative bevelled tip profiles and come in a broad range of sizes.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?